期刊文献+

PARP抑制剂奥拉帕利的合成及晶型A的制备 被引量:2

Synthesis of the PARP Inhibitor Olaparib and Prepration of Its Crystal Form A
下载PDF
导出
摘要 制备PARP抑制剂奥拉帕利晶型A.以2-氟-5-[(4-氧代-3,4-二氢酞嗪-1-基)甲基]苯甲酸为原料,与N-叔丁氧羰基哌嗪缩合为酰胺,脱去叔丁氧羰基保护,再与环丙基甲酸缩合,经三步反应制得奥拉帕利粗品.粗品经乙醇水溶液处理获得晶型A.目标产物的化学结构被1H-NMR,^(13)C-NMR,MS和元素分析确证,晶型经XRPD,DSC,TGA表征,总收率为51%.优化后的合成路线反应条件温和,操作简便,对环境友好,适宜工业化生产. The paper is to prepare crystal form A of PARP inhibitor Olaparib.The crude Olaparib was prepared from 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid by amidation with N-tert-butyloxycarbonylpiperazine,removing the protected N-boc group,and then condensation with cyclopropyl acid.Finally,the crude was treated with aqueous ethanol to produce crystal form A,which overall yield was 51%.The chemical structure of the target molecule was confirmed by 1H-NMR,^(13)C-NMR,MS and elemental analysis,and the crystal form was characterized by XRPD,DSC,TGA.In conclusion,the optimized synthetic route has the advantages of mild reaction conditions,operation easiness,environmental friendliness,and is suitable for industrial production.
作者 李宏名 胡瑞馨 张祥阳 郑维江 张娇 LI Hongming;HU Ruixin;ZHANG Xiangyang;ZHENG Weijiang;ZHANG Jiao(Xinxiang Medical University,Xinxiang 453003,China;College of Horticulture,Sichuan Agricultural University,Chengdu 611130,China;Sinopharm Chuankang Pharmaceutical Co.,Ltd,Chengdu 611731,China;Sichuan Kelun Pharmaceutical Research Institute Co.,Ltd,Chengdu 611138,China)
出处 《牡丹江师范学院学报(自然科学版)》 2022年第4期45-49,共5页 Journal of Mudanjiang Normal University:Natural Sciences Edition
基金 国家“重大新药创制”科技重大专项资助项目(2012ZX092021-013) 成都市高新区重点科技创新计划资助项目(15DFZD023)。
关键词 HBTU 酰胺化 多晶型 HBTU amidation polymorph
  • 相关文献

参考文献9

二级参考文献50

  • 1SIEGELR, MA J, ZOU Z, et al. Cancer statistics[J]. CA Cancer J Clin, 2014,64( 1 ) :9 - 29.
  • 2AstraZeneca AB. Lynparza 50 mg hard capsules: EU summary ofproduct characteristics[ EB/OL], 2014. http ://www. ema. euro- pa. eu/ema.
  • 3AstraZeneca Pharmaceuticals LP. LynparzaTM (olaparib) cap- sules, for oral use : US prescribing information ~ EB/OL ]. 2014. http ://www. accessdata, fda. gov/scripts/cder/drugsatfda/index. cfm.
  • 4BRYANT HE, SCHULTZ N, THOMAS HD, et al. Specific kill- ing BRCA2-deficient tumours with inhibitors of poly ( ADP-ri- bose) polymerase [ J ]. Nature, 2005, 434 ( 7035 ) : 913 - 917.
  • 5BURGESS M, PUHALLA S. BRCA l/2-mutation retated and sporadic breast and ovarian cancers: more alike than different [J]. Front Oncol, 2014, 4:19.
  • 6EMMA DD. Olararib: First global approval[ J]. Drugs, 2015, 75(2) :231 -240.
  • 7LEDERMANN J, HARTER P, GOURLEY C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer [J]. NEnglJMed, 2012, 366(15):1382-1392.
  • 8MATULONIS UA, HARTER P, GOURLEY C, et al. Analysis of intermediate clinical endpoints from a phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [ abstract no. 132 ~ I J]. Gyne- col Oneo1,2014,133 ( Suppl 1 ) : $54 - $55.
  • 9LEDERMANN J, HARTER P, GOURLEY C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of out- comesby BRCA status in a randomized phase 2 trial~ J]. Lancet Oncol, 2014,15(8) :852 -861.
  • 10KAYE SB, LUBINSKI J, MATULONIS U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibi- tor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer [ J]. J Clin Oncol,2011,30(4) :372 -379.

共引文献9

同被引文献5

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部